Product Description
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer|Glioblastoma|Breast Cancer
Phase 1: Oncology Unspecified|Colorectal Cancer|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02860780 |
I4D-MC-JTJL | P1 |
Completed |
Colorectal Cancer|Non-Small-Cell Lung Cancer |
2017-05-15 |
2024-06-26 |
Primary Endpoints|Treatments |
|
NCT01393990 |
I1D-MC-JIAD | P1 |
Completed |
Oncology Unspecified |
2013-02-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT02364206 |
GLYRad | P2 |
Completed |
Glioblastoma |
2019-08-01 |
2019-08-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT01663857 |
I1D-MC-JIAE | P2 |
Completed |
Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer |
2017-05-25 |
12% |
2019-05-30 |
Patient Enrollment|Treatments |
NCT02322853 |
OLYMPE | P2 |
Terminated |
Breast Cancer |
2017-04-01 |
2025-02-07 |
Primary Endpoints |